Belite Bio, Inc (BLTE)

Market Cap	2.13B
Revenue (ttm)	n/a
Net Income (ttm)	-35.29M
Shares Out	30.61M
EPS (ttm)	-1.22
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	165,438
Open	69.90
Previous Close	69.90
Day's Range	62.33 - 70.90
52-Week Range	31.01 - 70.90
Beta	-1.60
Analysts	Strong Buy
Price Target	59.00 (-15.36%)
Earnings Date	Nov 12, 2024

About BLTE

Belite Bio, Inc, a clinical stage biopharmaceutical drug development company, engages in the research and development of novel therapeutics targeting retinal degenerative eye diseases with unmet medical needs in the United States. The company’s lead product candidate is LBS-008 (Tinlarebant), an orally administered once-a-day tablet for maintaining the health and integrity of retinal tissues in autosomal recessive Stargardt disease and geographic atrophy patients. It is also developing LBS-009, an anti-retinol binding protein 4 oral therapy tha...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Apr 29, 2022
• Employees: 20
• Stock Exchange: NASDAQ
• Ticker Symbol: BLTE
• Website: https://www.belitebio.com

Analyst Forecast

According to 4 analysts, the average rating for BLTE stock is "Strong Buy." The 12-month stock price forecast is $59.0, which is a decrease of -15.36% from the latest price.

Price Target

$59.0

(-15.36% downside)

Analyst Consensus: Strong Buy